Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4690602

CCOc1ccc(-c2cc3nc(N)nc(N)c3c3ccn(C)c23)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2R P25116 1/20 0.45
DHFR P00374 3/20 0.39
HSP90AA1 P07900 1/20 0.38
PRKAB2 O43741 1/20 0.38
PRKAG1 P54619 1/20 0.38
PRKAA2 P54646 1/20 0.38
PRKAA1 Q13131 1/20 0.38
PRKAG3 Q9UGI9 1/20 0.38
PRKAG2 Q9UGJ0 1/20 0.38
PRKAB1 Q9Y478 1/20 0.38
HSD17B10 Q99714 2/20 0.37
LMNA P02545 2/20 0.36
KDM4E B2RXH2 2/20 0.36
NPC1 O15118 2/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
RAB9A P51151 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MEN1 O00255 2/20 0.36
MAPT P10636 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4688905 0.91 DHFR (0.40) DHFRKDM4ESLC2A1
Trifluoroacetic Acid SCHEMBL4692084 0.91 DHFR (0.40) F2RDHFRSLC2A1
SCHEMBL4688696 0.91 F2R (0.53) F2RDHFRMEN1MAPTKMT2A
Trifluoroacetic Acid SCHEMBL4691235 0.89 F2R (0.43) F2RDHFRSLC2A1
Trifluoroacetic Acid SCHEMBL4692244 0.88 DHFR (0.42) DHFRHSP90AA1SLC2A1
Trifluoroacetic Acid SCHEMBL4689027 0.88 DHFR (0.42) DHFRSLC2A1
Trifluoroacetic Acid SCHEMBL4688071 0.88 DHFR (0.42) F2RDHFRHSP90AA1SLC2A1
Trifluoroacetic Acid SCHEMBL4690263 0.88 DHFR (0.42) F2RDHFRHSP90AA1SLC2A1
Trifluoroacetic Acid SCHEMBL4693993 0.87 DHFR (0.41) DHFRHSP90AA1KDM4ESLC2A1
Trifluoroacetic Acid SCHEMBL4693908 0.87 DHFR (0.41) DHFRSLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1628979-B1 DIAMINOPYRROLOQUINAZOLINES COMPOUNDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS HOFFMANN LA ROCHE (CH) 2008-03-19 EP disclosed
US-20070270445-A1 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors BERTHEL STEVEN J 2007-11-22 US disclosed
US-7262297-B2 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors HOFFMANN-LA ROCHE INC. (US) 2007-08-28 US disclosed
US-20040235872-A1 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors BERTHEL STEVEN JOSEPH (US) 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235872-A1 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors PTPN5, PPP5C, PTP4A2 F2R 3381/4885DHFR 289/4885HSP90AA1 2880/4885
US-20070270445-A1 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors PTPN5, DUSP15, PPP5C F2R 3648/4885DHFR 339/4885HSP90AA1 2234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.